Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
The Lancet. Oncology|September 11, 2012
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trialTim Eisen, Heikki Joensuu, Paul D Nathan, et al.
BMC Medicine|October 4, 2019
The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohortTobias Klatte, Kevin M Gallagher, Luca Afferi, et al.
BMC Cancer|November 16, 2019
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinomaHannah L Buckley, Fiona J Collinson, Gemma Ainsworth, et al.
The Lancet. Oncology|May 19, 2015
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trialNicole Basset-Seguin, Axel Hauschild, Jean-Jacques Grob, et al.
World Journal of Urology|August 3, 2018
External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinomaLorenzo Marconi, Roderick de Bruijn, Erik van Werkhoven, et al.
European Journal of Dermatology : EJD|January 31, 2019
Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE studyJohan Hansson, Karen Bartley, Thomas Karagiannis, et al.
European Urology Focus|February 11, 2019
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted TherapyPeter E Hall, Scott T C Shepherd, Janet Brown, et al.
Cancer Discovery|October 22, 2020
Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body SiteJoanna C Fowler, Charlotte King, Christopher Bryant, et al.
BMC Cancer|November 19, 2021
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocolStephan Ursprung, Helen Mossop, Ferdia A Gallagher, et al.
The New England Journal of Medicine|August 23, 2013
Pazopanib versus sunitinib in metastatic renal-cell carcinomaRobert J Motzer, Thomas E Hutson, David Cella, et al.
Pageof 4